Auris Medical AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Subsidiary
- Established
- 2003-04-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.aurismedical.com
Clinical Trials
35
Active:28
Completed:7
Trial Phases
3 Phases
Phase 1:23
Phase 2:4
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Phase 1
23 (76.7%)Phase 2
4 (13.3%)Phase 3
3 (10.0%)AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery
Phase 2
Completed
- Conditions
- Vestibular Vertigo
- Interventions
- Other: Intranasal PlaceboDrug: Intranasal DrugDrug: Oral Tablet
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Auris Medical AG
- Target Recruit Count
- 124
- Registration Number
- NCT03908567
- Locations
- 🇫🇷
CHP Clairval, Marseille, France
AM-111 in the Treatment of Acute Inner Ear Hearing Loss
Phase 3
Completed
- Conditions
- Hearing Loss
- Interventions
- Other: PlaceboDrug: AM-111 0.4 mg/mlDrug: AM-111 0.8 mg/ml
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Auris Medical AG
- Target Recruit Count
- 256
- Registration Number
- NCT02561091
- Locations
- 🇧🇬
Please check link to study webpage below for more study sites, Sofia, Bulgaria
AM-101 in the Treatment of Acute Tinnitus 3
Phase 3
Completed
- Conditions
- Tinnitus
- Interventions
- Drug: AM-101Drug: Placebo
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Auris Medical AG
- Target Recruit Count
- 893
- Registration Number
- NCT02040194
- Locations
- 🇩🇪
Please check the study webpage below for a study site list, Munich, Germany
AM-101 in the Treatment of Post-Acute Tinnitus 2
Phase 3
Completed
- Conditions
- Tinnitus
- Interventions
- Drug: AM-101
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Auris Medical AG
- Target Recruit Count
- 487
- Registration Number
- NCT02040207
- Locations
- 🇩🇪
Investigational site, Munich, Germany
Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus
Phase 2
Completed
- Conditions
- Tinnitus
- Interventions
- Drug: AM-101
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Auris Medical AG
- Target Recruit Count
- 248
- Registration Number
- NCT00860808
- Locations
- 🇩🇪
Bundeswehrkrankenhaus Ulm, Ulm, Germany
- Prev
- 1
- 2
- Next
News
No news found